CSIMarket



Watson Pharmaceuticals Inc  (WPI)
Other Ticker:  
 
    Sector  Consumer Non Cyclical    Industry Legacy
   Industry Legacy
   Sector  Consumer Non Cyclical
 


Watson Pharmaceuticals Inc Segments

 
Branded pharmaceutical products
   9.44 % of total Revenue
Generic pharmaceutical products
   71.65 % of total Revenue
Distribution
   18.91 % of total Revenue
 

Business Segments (Sep. 30, 2012)
Revenues
(in millions $)
III. Quarter
%
(of total Revenues)
(Sep. 30, 2012)
Income
(in millions $)
III. Quarter
%
(Profit Margin)
Branded pharmaceutical products
121.30 9.44 % -6.20 -
Generic pharmaceutical products
920.90 71.65 % 326.20 35.42 %
Distribution
243.00 18.91 % 13.90 5.72 %
Total
1,285.20 100 % 333.90 25.98 %

• View Income Statement • View Competition by Segment • View Annual Report

Growth rates by Segment (Sep. 30, 2012)
Y/Y Revenue
%
III. Quarter
Q/Q Revenue
%
(Sep. 30, 2012)
Y/Y Income
%
III. Quarter
Q/Q Income
%
Branded pharmaceutical products
9.97 % 1.68 % - -
Generic pharmaceutical products
14.75 % -7.45 % 23.14 % -12.12 %
Distribution
43.96 % 0.87 % 33.65 % 36.27 %
Total
18.82 % -5.17 % 11.08 % -17.27 %

• View Growth rates • View Competitors Segment Growth • View Market Share

To get more information on Watson Pharmaceuticals Inc's Branded pharmaceutical products, Generic pharmaceutical products, Distribution, Total segment. Select each division with the arrow.

  Watson Pharmaceuticals Inc's

Business Segments Description



Branded Pharmaceutical Products

Newly developed pharmaceutical products are normally patented and, as a result, generally are offered by a single provider when first introduced to the market.  We currently market a number of patented products to physicians, hospitals, and other markets that we serve. We also market certain trademarked off-patent products directly to healthcare professionals. We classify these patented and off-patent trademarked products as our branded pharmaceutical products. 

Our branded pharmaceutical business currently develops, manufactures, markets, sells and distributes products primarily through the following sales and marketing groups:

• Women’s Health

• General Products

• Urology

• Nephrology

We market our branded products through these sales and marketing groups, represented by 768 sales professionals. Each of our specialized sales and marketing groups focuses on physicians who specialize in the diagnosis and treatment of different medical conditions and each group offers products to satisfy certain needs of these physicians. There are several branded products such as Oxytrol®, which are applicable to multiple physician audiences and each of the sales groups promotes those products to their physician audiences. We believe this focused sales and marketing approach enables us to foster close professional relationships with physicians and cover the primary care physicians who also prescribe in selected therapeutic areas. We generally sell our branded products under the “Watson Pharma” and the “Oclassen® Dermatologics” labels.

Our sales and marketing groups have targeted selected therapeutic areas predominately because of their potential growth opportunities and the size of the physician audience. Our expanded primary care sales force (consisting of both Watson and Ventiv employees) supports the specialty therapeutic areas by promoting products from each of these areas to primary care physicians and other specialties, who fall outside of the established therapeutic areas. We believe that the nature of these markets and the identifiable base of physician prescribers provide us with the opportunity to achieve significant market penetration through our specialized sales forces. Many of our branded products realize higher profit margins than our generic products. We intend to continue to expand our branded product portfolio through internal product development, strategic alliances and acquisitions.

WATSON BRANDED PRODUCT

ACTIVE INGREDIENT

THERAPEUTIC CLASSIFICATION

Actigall®

Ursodiol

Dissolution of gallstones

Androderm®

Testosterone (transdermal patch)

Male hormone replacement

Condylox®

Podofilox

Genital warts

Ferrlecit®

Sodium ferric gluconate in sucrose injection

Hematinic

Fioricet®

Butalbital, caffeine and acetaminophen

Barbiturate and analgesic

Fiorinal®

Butalbital, caffeine and aspirin

Barbiturate and analgesic

INFeD®

Iron dextran

Hematinic

Levora®

Levonorgestrel and ethinyl estradiol

Oral contraceptive

Low-OgestrelTM

Norgestrel and ethinyl estradiol

Oral contraceptive

Microgestin®

Norethindrone acetate and ethinyl estradiol

Oral contraceptive

Microzide®

Hydrochlorothiazide

Anti-hypertensive

MonoNessa®

Norgestimate ethinyl estradiol

Oral contraceptive

Necon®

Norethindrone and ethinyl estradiol

Oral contraceptive

Necon 7/7/7®

Norethindrone and ethinyl estradiol

Oral contraceptive

Nor-QD®

Norethindrone

Oral contraceptive

Norco 10s®

Hydrocodone bitartrate & acetaminophen

Analgesic

Oxytrol®

Oxybutnin (transdermal patch)

Overactive bladder

TriNessaTM

Norgestimate and ethinyl estradiol

Oral contraceptive

Tri-Norinyl®

Norethindrone and ethinyl estradiol

Oral contraceptive

Trivora®

Levonorgestrel and ethinyl estradiol

Oral contraceptive

Zovia®

Ethynodiol diacetate and ethinyl estradiol

Oral contraceptive

WOMEN’S HEALTH

Our Women’s Health product lines include oral contraceptives, a genital warts treatment, a hormone replacement therapy and a visual cervical screening device.  Currently, we have a total of 17 oral contraceptives in our product portfolio.  We market our Women’s Health products primarily to obstetricians and gynecologists.

GENERAL PRODUCTS AND UROLOGY

Our General Products and Urology product lines include urology, anti-hypertensive, neurology, psychiatry, pain management and dermatology products. Currently, we have a total of 20 products being marketed through this marketing group.  We market these products to urologists and primary care physicians, as well as endocrinologists.

NEPHROLOGY

Our Nephrology product line consists of products for the treatment of iron deficiency anemia. We generally market our Nephrology products to nephrologists and dialysis centers. Our primary product in the Nephrology group is Ferrlecit®, which is indicated for patients undergoing hemodialysis in conjunction with erythropoietin therapy. . Ferrlecit® (sodium ferric gluconate complex in sucrose injection), introduced in 1999, was granted a five-year exclusivity period by the FDA as a new chemical entity. This exclusivity period ended in February 2004. We have submitted a pediatric study to the Ferrlecit® NDA which could extend this exclusivity period for an additional six months.

Generic Pharmaceutical Products

When patents or other regulatory exclusivity no longer protect a branded product, opportunities exist to introduce off-patent or generic counterparts to the branded product. These generic products are the therapeutic equivalent to their brand name counterparts and are generally sold at prices significantly less than the branded product. As such, generic pharmaceuticals provide an effective and cost-efficient alternative to branded products.

Watson is a leader in the development, manufacture and sale of generic pharmaceutical products. We currently market more than 120 generic pharmaceutical products.  With respect to generic products, our strategy is to continue to target generic drugs that are difficult to formulate or manufacture or that will complement or broaden our existing product lines. Since the prices and unit volumes of our branded products will likely decrease upon the introduction of generic alternatives, we also intend to develop generic alternatives to our branded products where market conditions and the competitive environment justify such activities. 

WATSON GENERIC PRODUCT

COMPARABLE
BRAND NAME

BRAND HOLDER

THERAPEUTIC CLASSIFICATION

Butalbital, aspirin, caffeine and codeine (BACC)

Fiorinal®
w/codeine

Watson Pharmaceuticals

Analgesic

Carisoprodol

Soma®

Medpointe

Muscle relaxant

Cyclobenzaprine

Flexeril®

Merck & Co., Inc.

Muscle relaxant

Folic acid

Folvite®

Wyeth

Hematinics, Others

Glipizide ER

Glucotrol XL®

Pfizer Laboratories

Anti-diabetic

Hydrocodone bitartrate/ acetaminophen

Lorcet®

Forest Pharmaceuticals

Analgesic

Hydrocodone bitartrate/ acetaminophen

Vicodin®

Abbott Laboratories

Analgesic

Hydroxychloroquine

Plaquenil®

Sanofi-Synthelabo

Anti-malarial

Hydroxyzine

Atarax®

Pfizer Laboratories

Anti-anxiety

Lisinopril

Zestril®

AstraZeneca

Anti-hypertensive

Lorazepam

Ativan®

Wyeth

Tranquilizer

Meprobamate

Miltown®, Equanil®

Medpointe, Wyeth

Anti-anxiety

Metformin

Glucophage®

Bristol-Myers Squibb

Anti-diabetic

Minocycline

Minocin®

Wyeth

Anti-infective systemic

Nicotine polacrilex gum

Nicorette®

GlaxoSmithKline

Aid to smoking cessation

Nicotine transdermal system

Habitrol®

Novartis

Aid to smoking cessation

Nifedipine ER

Adalat CC®

Bayer AG

Anti-hypertensive

Oxycodone/acetaminophen

Percocet®

Endo Pharmaceuticals

Analgesic

Promethazine

Phenergan®

Wyeth

Antihistamine

Propafenone hydrochloride

Rythmol®

Abbott Laboratories

Anti-arrhythmic

Pharmaceutical Distribution Operations

Our distribution business, which consists of our Anda, Anda Pharmaceuticals and Valmed (also known as VIP) subsidiaries (collectively “Anda”), distributes primarily generic pharmaceutical products to independent pharmacies, alternate care providers (hospitals, nursing homes and mail order pharmacies) and pharmacy chains, and generic products and certain selective brand products to physicians’ offices. Additionally, we sell to buying groups, which are independent pharmacies that band together to enhance their buying power. We believe that we are able to effectively compete in the distribution market, and therefore optimize our market share, based on three critical elements: (i) very competitive pricing, (ii) responsive customer service that includes, among other things, next day delivery to the entire U.S. and high levels of inventory for approximately 7,000 shelf-keeping units (SKUs), and (iii) well established telemarketing relationships with our customers, supplemented by our electronic ordering capabilities. While most of the approximate 7,000 SKUs in our distribution operations are for products we purchase from third party manufacturers, we also utilize these operations for the sale and marketing of our, and our collaborative partners’, generic products. We are the only U.S. generic pharmaceutical company that has meaningful distribution operations with direct access to independent pharmacies and we believe that our distribution operation is a strategic asset in the national distribution of generic pharmaceuticals

   

Sales by Geography Competition By Business Segments Company Profile
       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

GLAQ's Profile

Stock Price

GLAQ's Financials

Business Description

Fundamentals

Charts & Quotes

GLAQ's News

Suppliers

GLAQ's Competitors

Customers & Markets

Economic Indicators

GLAQ's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2021 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071